Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is difficult to eradicate due to its resilient nature. Portal vein is often involved in tumors of large size, which exclude the patient from surgical resection and local ablative therapy, such as percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) be...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 18; no. 46; pp. 6861 - 6864 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
14.12.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Hepatocellular carcinoma (HCC) is difficult to eradicate due to its resilient nature. Portal vein is often involved in tumors of large size, which exclude the patient from surgical resection and local ablative therapy, such as percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) because they were considered neither effective nor safe. Currently, there is almost no effective treatment for HCC of such condition. As a unique antitumor agent in form of lipophilic fluid for local injection, para-toluenesulfonamide (PTS) produces mild side effects while necrotizing the tumor tissues quickly and efficiently. Being largely different from both PEI and RFA therapies, PTS can disseminate itself in tumors more easily than other caustic agents, such as alcohol. So PTS may offer additional benefit to HCCs with vascular involvement. We herein describe a 70-year-old HCC patient who was treated with the combination of PTS injection and transcatheter arterial chemoembolization, resulting in a significantly improved clinical prognosis. |
---|---|
Bibliography: | 14-1219/R Hepatocellular carcinoma (HCC) is difficult to eradicate due to its resilient nature. Portal vein is often involved in tumors of large size, which exclude the patient from surgical resection and local ablative therapy, such as percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) because they were considered neither effective nor safe. Currently, there is almost no effective treatment for HCC of such condition. As a unique antitumor agent in form of lipophilic fluid for local injection, para-toluenesulfonamide (PTS) produces mild side effects while necrotizing the tumor tissues quickly and efficiently. Being largely different from both PEI and RFA therapies, PTS can disseminate itself in tumors more easily than other caustic agents, such as alcohol. So PTS may offer additional benefit to HCCs with vascular involvement. We herein describe a 70-year-old HCC patient who was treated with the combination of PTS injection and transcatheter arterial chemoembolization, resulting in a significantly improved clinical prognosis. Hepatocellular carcinoma Para-toluenesulfonamide Antitumor agent Transcatheter arterial chemoembolization Therapy ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 Correspondence to: Dr. An-Ren Kuang, Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. he41@sohu.com Telephone: +86-28-85423270 Fax: +86-28-85423278 Author contributions: He Q and Kuang AR conceived and designed the study and prepared the manuscript; Guan YS and Liu YQ acquired and analyzed the data. |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.v18.i46.6861 |